Cancer Drug Design and Discovery

2. Revised Auflage 2013
ISBN: 978-0-12-396521-9
Verlag: Elsevier Science

Buch, Englisch, 640 Seiten, Format (B × H): 195 mm x 244 mm, Gewicht: 1564 g

Cancer Drug Design and Discovery, Second Edition is an important reference on the underlying principles for the design and subsequent development of new anticancer small molecule agents. New chapters have been added to this edition on areas of particular interest and therapeutic promise, including cancer genomics and personalized medicine, DNA-targeted agents and more. This book includes several sections on the basic and applied science of cancer drug discovery and features those drugs that are now approved for human use and are in the marketplace, as well as those that are still under development. By highlighting some of the general principles involved in taking molecules through basic science to clinical development, this book offers a complete and authoritative reference on the design and discovery of anticancer drugs for translational scientists and clinicians involved in cancer research.

Zielgruppe

<p>Translational researchers and clinicians interested in modern drug discovery, cancer biology and medicine, as well as graduate and undergraduate students in pharmacy, pharmacology or medicinal and biological chemistry. </p>

Autoren/Hrsg.

Neidle, Stephen

Fachgebiete

• Naturwissenschaften Chemie Chemie Allgemein Pharmazeutische Chemie, Medizinische Chemie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pharmakologie, Toxikologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Onkologie, Krebsforschung
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Pharmazie

Inhaltsverzeichnis

Introduction - Stephen Neidle

Foreword - Hilary Calvert

Part I. Basic Principles and methodology

Modern cancer drug discovery: integrating targets, technologies and treatments - Paul Workman and Ian Collins

Pharmacogenomics and personalised medicines in cancer treatment - Wei-Peng Yong, Ross Soo and Federico Innocenti

Structural biology and anticancer drug design - Puja Pathuri, David Norton, Henriette Willems, Dominic Tisi and Harren Jhoti

Part II. Drugs in the laboratory and clinic

Temozolomide: from cytotoxic to molecularly-targeted agent - Malcolm Stevens

Temozolomide: patents and the perils of invention - Malcolm Stevens

A new generation of cell-targeted drugs for cancer treatment - Paola B. Arimondo, Nicolas Guilbaud and Christian Bailly

Inhibition of DNA repair as a therapeutic target - Stephany Veuger and Nicola J Curtin Inhibitors of tumour angiogenesis - Adrian L. Harris and Daniele G Generali

The Renaissance of CYP17 Inhibitors for the Treatment of Prostate Cancer - Qingzhong Hu and Rolf W. Hartmann

Apoptosis in Cancer: Mechanisms, Deregulation and Therapeutic Targeting - Zahid H Siddik

Targeting the MDM2-p53 protein-protein interaction: design, discovery and development of novel anticancer agents - Ian R Hardcastle

Targeting altered metabolism - emerging cancer therapeutic strategy - Minsuh Seo, Robert Blake Crochet and Yong-Hwan Lee

Inhibitors of the Phosphatidylinositol 3-kinase (PI3K) Pathway - William A Denny and Gordon W. Rewcastle

Antibody-drug conjugates delivering DNA cytotoxics - John A Hartley

Inhibition of telomerase: promise, progress and potential pitfalls - Christopher G. Tomlinson, Scott B. Cohen and Tracy M. Bryan

Targeting B-RAF: the discovery and development of B-RAF inhibitors - Phillip A Harris

Part III. The reality of cancer drugs in the clinic

Failure Modes in Anticancer Drug Discovery and Development - Richard A. Walgren and Christopher. A. Slapak

Anticancer drug registration and regulation: current challenges and possible solutions - David Taylor, Erling Donnelly and Silvia Chioato

Über Autor(innen)

Neidle, Stephen
Stephen Neidle is an Emeritus Professor of Chemical Biology at University College London, where he has also been the Director of Research in the School of Pharmacy. He has published over 500 primary papers and reviews and is a principal inventor on 14 patent filings. He has also written and edited several books on nucleic acids and anti-cancer drugs.